Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.

ABSTRACT:

Purpose

To evaluate the risks and quality-of-life (QoL) outcomes of fluocinolone acetonide implant versus systemic therapy with corticosteroid and immunosuppression when indicated for intermediate uveitis, posterior uveitis, and panuveitis.

Design

Additional follow-up of a randomized trial cohort.

Participants

Two hundred fifty-five patients with intermediate uveitis, posterior uveitis, or panuveitis, randomized to implant or systemic therapy.

Methods

Randomized subjects with intermediate uveitis, posterior uveitis, or panuveitis (479 eyes) were followed up over 54 months, with 79.2% completing the 54-month visit.

Main outcome measures

Local and systemic potential complications of the therapies and self-reported health utility and vision-related and gene

SUBMITTER: Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group 

PROVIDER: S-EPMC4581951 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature